Atezolizumab

(Tecentriq®)

Tecentriq®

Latest News

loading GIF

Drug updated on 4/26/2024

Dosage FormInjection (intravenous; 840 mg/14 mL [60 mg/mL], 1200 mg/20 mL [60 mg/mL])
Drug ClassProgrammed death-ligand1 blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.
  • Indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.
  • Indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.
  • Indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • Indicated in combination with paclitaxel protein-bound and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • Indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq.
  • Indicated in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
  • Indicated in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
  • Indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Atezolizumab (Tecentriq) is indicated for the treatment of various conditions including unresectable or metastatic Alveolar Soft Part Sarcoma (ASPS), non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer, hepatocellular carcinoma, and BRAF V600 mutation-positive melanoma. Its effectiveness varies across these indications.
  • The information was derived from 35 systematic reviews/meta-analyses focused on the efficacy, safety, and application of atezolizumab in different populations and subgroups.
  • In patients with Unresectable Hepatocellular Carcinoma (uHCC), a combination therapy involving atezolizumab and bevacizumab has been effective even in those with CTP-A or CTP-B cirrhosis. This combination therapy also showed longer progression-free survival rates compared to tyrosine kinase inhibitors.
  • For metastatic NSCLC patients, especially when combined with chemotherapy agents like bevacizumab, Tecentriq displayed improved overall survival rates as well as tolerability. It particularly outperformed monotherapy and chemotherapy in enhancing both objective response rates and progression-free survival when used for PD-L1 high expression tumors.
  • Studies have revealed manageable safety profiles for Tecentriq alone or in combination therapies without any significant increase in grade ≥3 adverse events compared to control arms or chemotherapy treatments indicating its relative safety during clinical treatments.
  • Subgroup considerations reveal varying levels of efficacy based on factors such as PD-L1 levels, CNS metastases presence, smoking history among advanced NSCLC patients treated using combinations of chemotherapy drugs along with Tecentriq. However, combinations involving Bevacizumab consistently provided favorable PFS across all PD-L1 levels.
  • When directly compared against other systemic therapies such as Lenvatinib for advanced HCC, Tecentriq did not show superiority in terms of objective response rates, disease control rate, or progression-free survival, indicating the need for further head-to-head trials.
  • Toxicity analysis placed combinations involving Tecentriq as generally safe when compared with other treatments. However, attention should be paid to incidences of hepatotoxicity and pyrexia, which were noted as adverse events.

Product Monograph / Prescribing Information

Document TitleYearSource
Tecentriq (atezolizumab) prescribing information.2024Genentech, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.2023eClinicalMedicine
Activity and safety of first-line treatments for advanced melanoma: a network meta-analysis.2023European Journal of Cancer
Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.2023BMC Cancer
Anti-TIGIT therapies for solid tumors: a systematic review.2023ESMO Open
Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis. 2023Therapeutic Advances in Chronic Disease
Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. 2023Clinical and Experimental Hepatology
Meta-analysis of atezolizumab vs docetaxel in non-small cell lung cancer treatment outcomes.2023Alternative Therapies in Health Medicine
The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: a systematic review and network meta-analysis.2023Frontiers in Immunology
First- and second-line treatments for patients with advanced hepatocellular carcinoma in China: a systematic review.2022Current Oncology
Efficacy and safety of anti-PD1/PDL1 in advanced biliary tract cancer: a systematic review and meta-analysis.2022Frontiers in Immunology
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.2022Frontiers in Immunology
Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.2022BMC Cancer
Comparative efficacy and safety of anti-PD-1/PD-L1 for the treatment of non-small cell lung cancer: a network meta-analysis of 13 randomized controlled studies.2022Frontiers in Oncology
Addition of immune checkpoint inhibitors to chemotherapy vs chemotherapy alone as first-line treatment in extensive-stage small-cell lung carcinoma: a systematic review and meta-analysis.2022Oncology and Therapy
Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. 2021JNCI: Journal of the National Cancer Institute
Network meta-analysis comparing efficacy, safety and tolerability of anti-PD-1/PD-L1 antibodies in solid cancers. 2021Journal of Cancer
Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma. 2021OncoImmunology
The rapidly evolving landscape of first-line targeted therapy in metastatic urothelial cancer: a systematic review. 2021The Oncologist
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.2021Therapeutic Advances in Medical Oncology
Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis. 2021Medicine Open
Atezolizumab monotherapy or plus chemotherapy in first-line treatment for advanced non-small cell lung cancer patients: a meta-analysis. 2021Frontiers in Immunology
Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis. 2021European Review for Medical and Pharmacological Sciences
Comparative efficacy and safety of immunotherapeutic regimens with PD-1/PD-L1 inhibitors for previously untreated extensive-stage small cell lung cancer: a systematic review and network meta-analysis. 2021Current Oncology
Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. 2021Journal of Thoracic Oncology
Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis. 2021Journal of Cancer
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). 2021Gastroenterology
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer (review). 2021Cochrane Database of Systematic Reviews
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.2021BMC Cancer
Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.2020Current Oncology
Comparison of first-line treatments for patients with extensive-stage small cell lung cancer. 2020JAMA Network Open
Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis. 2020Therapeutic Advances in Medical Oncology
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis.2019Thoracic Cancer
The relative risk of immune-related liver dysfunction of PD-1/PD-L1 inhibitors versus chemotherapy in solid tumors: a meta-analysis of randomized controlled trials.2019Frontiers in Pharmacology
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non–small cell lung cancer and melanoma: network meta-analysis and systematic review.2019Frontiers in Pharmacology
Second-line systemic treatment for metastatic urothelial carcinoma: a network meta-analysis of randomized phase iii clinical trials.2019Frontiers in Oncology
Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis.2019Drug Design, Development, and Therapy

Clinical Practice Guidelines